Trans-Mucosal Drug Delivery Technology (TMDD)

Trans-Mucosal Drug Delivery Technology (TMDD)
Product Description

Trans-mucosal drug delivery technology is a novel application of hyaluronic acid’s biological, physiological, rheological, and structural properties. By utilizing specific formulations of hyaluronic acid, we have developed products for different indications and with different routes of administration. TMDD products are targeted to the lesion for controlled release of the drug in the appropriate environment. Besides increasing residence time in the targeted area, overall dose of the drug is decreased, reducing associated side effects. The newly developed drug, IBD98-M, makes full use of the viscoelasticity and mucoadhesive properties of hyaluronic acid, enabling a controlled sustained release of the active ingredient in the targeted area. This technology is also applied in our medical devices, TRUD, and GAF. TRUD is an enema for treatment for ulcerative colitis and GAF is a gel for anal fissure healing. Both devices exploit that hyaluronic acid is biocompatible, shows no significant side effect, facilitates healing and efficiently induces the remission of inflammation/damage on the target lesion. Both of the products have received CE certificate for Class II medical device.

Holy Stone Healthcare Co., Ltd.

  • TW
  • 2024
    On CPHI since
  • 100 - 249
    Employees
Company types
Pharmaceutical company

Holy Stone Healthcare Co., Ltd.

  • TW
  • 2024
    On CPHI since
  • 100 - 249
    Employees
Company types
Pharmaceutical company

More Products from Holy Stone Healthcare Co., Ltd. (3)

  • HDD Technology: Hyaluronan Drug Delivery

    Product HDD Technology: Hyaluronan Drug Delivery

    Holy Stone Healthcare focuses on biopolymers to develop novel drug delivery technologies. Our "Biopolymer drug delivery platform" exploits the biological safety, compatibility, degradability and other characteristics of natural polysaccharides. We have made full use of non-toxic, non-immunogenic, non-infl...
  • Hyaluronic Acid Conjugated Drugs, HACD

    Product Hyaluronic Acid Conjugated Drugs, HACD

    We have developed a “targeting” treatment based on the fact that hyaluronic acid specifically combines with cell surface receptors, glycoprotein CD44 (cluster of differentiation 44) and RHAMM (receptor for hyaluronan mediated motility), which are highly expressed in certain cancer cells. We then select ant...
  • Multi-Layer Coating Pellet Technology (MLCP)

    Product Multi-Layer Coating Pellet Technology (MLCP)

    Multi-layer coating pellet technology (MLCP) is a manufacturing technology developed under the Hyaluronan Drug Delivery technology platform. Using an advanced fluid bed technology, we coat pellets with a patented formulation of drug and HA in multiple layers to produce an oral dosage form targeted to relea...

Holy Stone Healthcare Co., Ltd. resources (1)